Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Wimits Pharmaceuticals Pvt. Ltd

Pharmaceutical manufacturer · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Pharmaceutical manufacturer
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000789 13 linked products · source seen 9 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx13product presentations
G5generic molecules
DF2dosage-form groups
TA2therapeutic areas
PKR13current price records
REG10registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage92%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixWimits Pharmaceuticals Pvt. LtdShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/wimits-pharmaceuticals-pvt-ltdGenerated 9 Aug 2026Pain & musculoskeletal7 · 54%Anti-infectives6 · 46%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioWimits Pharmaceuticals Pvt. LtdDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/wimits-pharmaceuticals-pvt-ltdGenerated 9 Aug 202613presentationsSuspension7 · 54%Injection6 · 46%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionWimits Pharmaceuticals Pvt. LtdCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/wimits-pharmaceuticals-pvt-ltdGenerated 9 Aug 202612comparable productsBelow market median5 · 42%Near market median3 · 25%Above market median4 · 33%Company median price position-0.5%Lowest-price equivalents4Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsWimits Pharmaceuticals Pvt. LtdCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/wimits-pharmaceuticals-pvt-ltdGenerated 9 Aug 2026M/s. Genix Pharma (Pvt) Ltd.5 shared100% overlapPharmasol (Pvt) Ltd.5 shared100% overlapBosch Pharmaceuticals (Pvt) Ltd.5 shared100% overlapMacter International Limited5 shared100% overlapMediate Pharmaceutical Pvt Ltd5 shared100% overlapValor Pharmaceuticals5 shared100% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Pain & musculoskeletal7 products · 54%
Anti-infectives6 products · 46%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Analgesics / NSAIDs7 products · 54%
Third-generation cephalosporins3 products · 23%
Macrolide antibacterials2 products · 15%
Oxazolidinone antibacterials1 products · 8%
Formulation footprint

Dosage forms

Suspension7 products
Injection6 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 IBUPROFENIbuprofen 6presentations 100 mg/5 mL, 400 mg/4 mL, 800 mg/8 mL · Suspension, Injection #2 CeftazidimeCeftazidime 3presentations 1 g, 250 mg, 500 mg · Injection #3 AzotraxAzithromycin 2presentations 100 mg/5 mL, 200 mg/5 mL · Suspension #4 DilozenLinezolid 1presentations 100 mg/5 mL · Suspension #5 MonadolParacetamol 1presentations 160 mg/5 mL · Suspension
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median542% of comparable products
Near market median3within ±5% of median
Above market median433% of comparable products
Lowest-price equivalents4ties included
Company median price position -0.5% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Dilozen 100 mg/5 mLLinezolid · Suspension · 60ml PKR 5.83/mL-46.7% vs market median Azotrax 200 mg/5 mLAzithromycin · Oral suspension · 15ml PKR 11.00/mL-42.0% vs market median Azotrax 100 mg/5 mLAzithromycin · Oral suspension · 30ml PKR 3.33/mL-33.4% vs market median IBUPROFEN 100 mg/5 mLIbuprofen · Suspension · 450ml PKR 0.74/mL-21.3% vs market median IBUPROFEN 100 mg/5 mLIbuprofen · Suspension · 90ml PKR 0.87/mL-7.8% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

M/s. Genix Pharma (Pvt) Ltd.290 products · 97 generics 5shared generics Pharmasol (Pvt) Ltd.251 products · 101 generics 5shared generics Bosch Pharmaceuticals (Pvt) Ltd.250 products · 73 generics 5shared generics Macter International Limited248 products · 91 generics 5shared generics Mediate Pharmaceutical Pvt Ltd239 products · 90 generics 5shared generics Valor Pharmaceuticals218 products · 97 generics 5shared generics
Regulatory & price activity

Observed database signals

Registration numbers10
Price-history records16
Products with price history2
Source records with multiple versions0
Latest MedInfoBase verification9 Aug 2026
Latest effective price date4 Aug 2026
Latest source observation9 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

7 results
Intelligence filter: Drug classAnalgesics / NSAIDs Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
IBUPROFEN Ibuprofen 100 mg/5 mL Suspension 450ml 077270 PKR 334.97 PKR 0.74/mL 21% below median
IBUPROFEN Ibuprofen 400 mg/4 mL Injection 4ml x 10's 119680 PKR 1,889.35 PKR 47.23/mL Near median
IBUPROFEN Ibuprofen 800 mg/8 mL Injection 10's 121577 PKR 3,816.10 PKR 381.61/vial/unit Near median
IBUPROFEN Ibuprofen 100 mg/5 mL Suspension 90ml 077270 PKR 78.52 PKR 0.87/mL 8% below median
IBUPROFEN Ibuprofen 100 mg/5 mL Suspension 120ml 077270 PKR 129.12 PKR 1.08/mL 14% above median
IBUPROFEN Ibuprofen 800 mg/8 mL Injection 1's 121577 PKR 397.55 PKR 397.55/vial/unit Near median
Monadol Paracetamol 160 mg/5 mL Suspension 120ml 121583 PKR 147.94 PKR 1.23/mL No comparator
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.